- About this Journal ·
- Abstracting and Indexing ·
- Aims and Scope ·
- Article Processing Charges ·
- Articles in Press ·
- Author Guidelines ·
- Bibliographic Information ·
- Citations to this Journal ·
- Contact Information ·
- Editorial Board ·
- Editorial Workflow ·
- Free eTOC Alerts ·
- Publication Ethics ·
- Reviewers Acknowledgment ·
- Submit a Manuscript ·
- Subscription Information ·
- Table of Contents
Advances in Urology
Volume 2011 (2011), Article ID 854792, 10 pages
Sexual Dysfunctions of HIV-Positive Men: Associated Factors, Pathophysiology Issues, and Clinical Management
Sexuality Studies Program (ProSex), Department and Institute of Psychiatry, Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo, Rua Dr. Ovidio Pires de Campos, 785, 05403-010 São Paulo, SP, Brazil
Received 1 July 2011; Accepted 21 August 2011
Academic Editor: Rany Shamloul
Copyright © 2011 Marco de Tubino Scanavino. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Sexual dysfunctions in HIV-positive men are associated with an increase in risky sexual behavior and decreased adherence to antiretroviral drug regimens. Because of these important public health issues, we reviewed the literature on the pathophysiology, associated factors and clinical management of sexual dysfunction in HIV-positive men. The goal was to investigate the current research on these issues. Literature searches were performed in June 2011 on PubMed, Web of Science, and PsycInfo databases with the keywords “AIDS” and “sexual dysfunction” and “HIV” and “sexual dysfunction”, resulting in 54 papers. Several researchers have investigated the factors associated with sexual dysfunction in HIV-positive men. The association between sexual dysfunction and antiretroviral drugs, particularly protease inhibitors, has been reported in many studies. The lack of standardized measures in many studies and the varying study designs are the main reasons that explain the controversial results. Despite some important findings, the pathophysiology of sexual dysfunction in the HAART era still not completely understood. Clinical trials of testosterone replacement therapy have shown the treatment to be beneficial to the improvement of sexual dysfunctions related to hypogonadism. However, there are not enough psychological intervention studies to make conclusions regarding the therapeutic effects of psychotherapy.
Highly active antiretroviral therapy (HAART) has previously been shown to provide the best clinical management for HIV-infected patients, as it decreases the prevalence of hypogonadism and advanced HIV disease, which are the principal causes of sexual dysfunction in people infected with HIV [1, 2]. However, the prevalence of sexual dysfunctions in the years since the advent of highly active antiretroviral therapy (HAART), which varies according to the cultural and methodological issues of the studies in question, includes high rates of erectile dysfunction (ED) (9–74%), ejaculatory disturbances (36–42%), and low sexual desire (LSD) (24–73%) .
In an English clinical study conducted in 2001 with 78 HIV-positive gay men, 69% reported one or more sexual problems. ED was reported by 38% of the men, which rose to 51% in the context of trying to use condoms. Loss of interest in sex was reported by 41%, and 24% experienced delayed ejaculation . From October 2002 to January 2003, a case-control Brazilian study nested in a cross-sectional population of individuals with AIDS found that almost 50% of the men reported ejaculatory symptoms, 33% reported ED, and 12% reported dyspareunia .
After receiving the diagnosis of HIV infection, it is common for people to experience negative moods and decrease the frequency of sexual activity, and those who remain sexually active most likely do so without adequate protection . Adherence to safe sex practices after HIV diagnosis may have a negative impact on the sexual functioning of most subjects . Individuals who are partnered are significantly more likely to maintain sexual activity than those who do not have a partner .
In a study with a convenience sample of 156 HIV-positive gay men and 155 HIV-negative gay men selected from the community and the internet who were matched for age and unprotected anal intercourse (UAI), the HIV-positive men were more likely to report ED and higher scores on the inhibition of arousal due to the threat of performance failure . The presence of ED associated with condom use has been reported by gay men. Risk cognitions such as wanting to lose oneself in sex, placing the responsibility for condom use to the active partner, and perceptions that condoms interfere with pleasure were significantly more likely to be endorsed by those who reported ED associated with condom use .
In addition, it must be considered that individuals who acquire HIV through sexual or parenteral (excluding blood transfusions) routes of infection are already part of a population that is at higher risk for sexual dysfunction, as many risk factors for HIV are also linked to the occurrence of sexual dysfunction such as conflicts with one’s sexual orientation or sexual identity, depression, and psychological problems related to self-image [9, 10].
Moreover, sexual dysfunction has an impact on the quality of life and very often leads to negative attitudes on the part of the individual, including poor adherence to antiretroviral regimens and to safer sex strategies [11–13]. HIV-infected people with sexual dysfunction who are nonadherent to antiretroviral regimens have an increased risk of transmission of drug-resistant strains because of higher-risk sexual behavior, higher HIV RNA concentrations in semen and cervical secretions , and inappropriate use of phosphodiesterase-5 (PDE-5) inhibitors without medical recommendations with higher likelihood of negative interaction with antiretrovirals [11, 12, 15].
Because of the increases in risky sexual behavior and decreased adherence to antiretroviral drugs reported in HIV-positive men with sexual dysfunctions, we decided to review the literature on the pathophysiology, associated factors, and clinical management of sexual dysfunctions in HIV-positive men. The goal of this review is to investigate the current research on these issues.
Literature searches were performed in June 2011 on the PubMed, Web of Science, and PsycInfo databases with the keywords “AIDS” and “sexual dysfunction,” which resulted in 36, 11, and 21 articles, respectively. These searches were also performed with the keywords “HIV” and “sexual dysfunction,” which resulted in 56, 12, and 22 articles, respectively. The abstracts were reviewed and the inclusion criteria required that the studies were clinical studies on the associated factors, pathophysiology, and clinical management of the sexual dysfunctions of HIV-positive men, and that they were published in English. Posters and abstracts of presentations in congress or scientific meetings were excluded from our search. Firstly, 20 studies were included and reviewed. After searching the reference lists of these papers, 34 more studies were reviewed, resulting in a total of 54 papers.
Fifty-four papers on the associated factors, pathophysiology, and clinical management of sexual dysfunction in HIV-positive males were reviewed.
3.1. Associated Factors
There are four important factors associated with sexual dysfunction in HIV/AIDS patients: mental, hormonal, pharmacological, and other morbid conditions. Table 1 lists the studies on these associated factors.
3.1.1. Mental Factors
A representative French study on 1,812 HIV outpatients who were being treated for HIV and reported having had at least one sexual partner in the 12 months prior to the survey showed an association between sexual difficulties and knowing more than four people who lives with HIV/AIDS, perceiving side effects as very disturbing, reporting lipodystrophy-related symptoms and having a high HIV-discrimination score in the prior 12 months. Moreover, CD4 cell levels, viral load titers, and CDC stage, and current HAART treatment at the time of the study were not associated with sexual difficulties. The authors recommended psychological support for HIV patients in order to improve the sexual aspects of their lives . Feelings of guilt from having acquired HIV via sexual transmission may be a mental factor that negatively influences the sexual response. This psychological factor may explain some reports of higher rates of sexual dysfunctions in homosexual and bisexual men [26, 27].
Depression is one of the most important mental factors associated with sexual dysfunctions . A study on 300 HIV-infected men found that older age and depression were associated positively with ED, and higher CD4 cell counts were associated negatively, then, and higher CD4 was considered protective regarding ED .
3.1.2. Hormonal Factors
Hypogonadism was one of the most frequent causes of sexual dysfunction before HAART. Currently, HIV-infected individuals may have higher testosterone levels than noninfected individuals.
The prevalence of hypogonadism has been lowered with the introduction of HAART, but it still remains the most common endocrine disorder of HIV-infected men .
Moreover, estradiol is often higher in men (50% of them) on HAART, possibly due to augmented peripheral conversion of androgens to estrogens in lipid tissues [30, 31]. However, the role of estradiol in HIV-related sexual dysfunctions is not clear. The expected decreased levels of gonadotropin hormones in the blood were not observed , and one study observed improved sexual function despite higher blood levels of estradiol . Hyperprolactinemia may be associated with sexual dysfunction as it decreases the release of gonadotropins and has been found in some HIV-positive individuals. However, one study found no difference in prolactin levels between patients with and without sexual difficulties .
3.1.3. Pharmacological Factors
Table 1 lists the studies on the association between antiretrovirals, particularly protease inhibitors, and sexual dysfunction.
Ejaculatory dysfunction has been shown to be associated with the use of didanosine  as well. Moreover, HIV-infected individuals use many other medications that are associated with decreased sexual responses. Medications such as ketoconazole, fluconazole, ganciclovir, megestrol, methadone, and cimetidine may decrease testosterone levels and cause sexual dysfunction [6, 32]. Antihypertensives, diuretics, hypolipemics, benzodiazepines, antidepressants, and antipsychotics are also associated with sexual dysfunctions [19, 32–34].
3.1.4. Comorbid Conditions
Some morbid conditions are common in HIV-infected individuals and some of them are often associated with sexual dysfunction, such as hepatopathy, diabetes, hyperlipidemia, hypertension, vascular disease, and alcohol dependence .
Peripheral neuropathy is a well-documented complication of both HIV infection by direct viral toxicity and HAART, most notably with thymidine analog nucleoside reverse transcriptase inhibitors. There is a significant association in HIV-positive men between peripheral neuropathy and delayed ejaculation .
Another study on 12 patients with ED reported neuropathy of the sacral region was associated with protease inhibitor use, particularly indinavir .
3.2. Pathophysiological Issues
One prospective, age- and sex-matched study in Nairobi on 25 patients (7 with asymptomatic HIV, 8 with AIDS-related complex, and 10 with AIDS) and 25 controls was evaluated for its autonomic functioning. Substantial autonomic dysfunctions were seen in AIDS patients relative to controls, and mild abnormalities in the majority of HIV-infected patients were found . This finding could explain the association between delayed ejaculation and peripheral neuropathy . The physiological process of ejaculation is under autonomic control via the hypogastric (sympathetic) and pudendal (parasympathetic) nerves .
Another relevant point regarding the pathophysiology of the sexual dysfunctions of this population is that many patients who are on HAART to treat their HIV infection and have lipodystrophy also have elevated estrogen levels and complain of low sexual desire. As a possible pathological mechanism, one can consider an increase in the number of fibroblasts and macrophages present in lipoatrophic areas that could convert testosterone to estrogen by intracellular aromatization. This process is known to be enhanced by increased levels of tumor necrosis factor, interleukin 6 (IL-6), and hydroxycorticosteroids present in many patients with HIV lipodystrophy .
In addition, a study on rabbits found estrogen receptors in the cavernous body of the penis and found pathophysiological changes in erectile function when rabbits were treated with continuous estrogen . Another study of older men found that the balance between testosterone (decreased) and estradiol (increased) is associated with ED .
Anecdotal reports suggest an association between protease inhibitor use and sexual dysfunctions, but only a few studies have found specific evidence for the link. These studies found a possible effect of the protease inhibitors on the binding of the steroids hormones with their receptors  or causing the blockade of androgen receptor , both actions could be related to sexual difficulties associated with protease inhibitors.
3.3. Clinical Management
The clinical management of sexual dysfunctions in HIV/AIDS patients involves clinical assessment, pharmacotherapy, psychotherapy, and psychoeducational approaches to safer sex. Table 2 lists the clinical management studies.
3.3.1. Clinical Assessment
In order to investigate the sexual functioning of HIV-infected people, the first point to consider is ensuring an appropriate doctor-patient relationship . It is important that professionals maintain an open-minded attitude and be free of judgments.
The clinical history contains the assessment of the patient’s immunological conditions, comorbidities, and medications. Severe immunological damage may indicate an AIDS diagnosis. Poor health undermines the overall physical condition and the sexual response. Nevertheless, hypogonadism should be investigated. Upon physical examination, gynecomastia and testicular atrophy may indicate hypogonadism . Hypogonadism is defined by low levels of testosterone (<300 nh/dL) in the early morning, with associated clinical manifestations, including sexual dysfunction, weight and muscle mass loss, fatigue, depressed mood, and anemia .
When sexuality is repressed, it can be difficult for individuals to fully experience sex and love in adolescence and young adult life . These experiences are fundamental to the sexual maturation process. When it fails because of sexual repression and possible internal conflicts regarding living the sexuality experience, it can undermine the sexual response. Other factors in an individual sexual history may be relevant to their experience of sexual dysfunction like sexual violence suffered during childhood and adolescence, which can also lead to serious psychological effects and sexual consequences [48–50].
An individual’s first sexual experiences with boys or girls, his/her first complete sexual relationship, and masturbation are all significant steps in the sexual maturation process, which involves gaining knowledge about one’s body (erogenous zones) and of the bodies of others. When a person has sexual difficulties in their early sexual experiences that they are not prepared to deal with, these experiences can promote a negative attitude regarding sex; new experiences will be avoided, thus undermining sexual maturation .
A person with sexual inexperience is at higher risk for sexual dysfunction , and, in turn, a person with sexual dysfunction is at higher risk for unsafe sexual behavior , even if infected by HIV.
Some specific gender issues are also important and should be investigated. For men, homosexual orientation presents a special vulnerability for sexual dysfunction, perhaps because of the process of accepting sexual orientation, the difficulties in dealing with poor acceptance by family and society, and problems with gender identity . Some studies have reported higher rates of sexual dysfunction in HIV-infected men who have sex with men .
Characteristics of Organic or Psychogenic Sexual Dysfunctions
It is also relevant to distinguish between characteristics of organic or psychogenic sexual dysfunction (Table 3) [23, 53–55]. Considering HIV infection, we could conclude that individuals who are seropositive but are in good health probably have sexual dysfunctions due to a psychogenic etiology, and individuals with poor immunological conditions or an AIDS diagnosis probably have sexual dysfunctions that are due to organic factors.
Some standardized instruments for the quick assessment of sexual responses can be used, as health practitioners often find it difficult to investigate the sex lives of their patients. For males, there is the International Index of Erectile Function (IIEF), which addresses the relevant domains of male sexual function (erectile function, orgasmic function, sexual desire, intercourse satisfaction, and overall satisfaction). This instrument is psychometrically tested and readily self-administered in research or clinical settings .
Laboratory assessment may involve a screening of sexual hormones including testosterone, estrogen, estradiol, prolactin, and gonadotropin. It is important to check the serum-free testosterone level or the levels of sex-hormone-binding globulin because they are usually increased in HIV-infected individuals . Preliminary evaluations can be accomplished by determining the free testosterone level because the total level may be falsely reassuring due to an elevation in sex-hormone-binding globulin, the principal binding protein for testosterone .
When organic etiology is suspected, more comprehensive evaluations can take place, such as Doppler ultrasonography to assess possible arterial obstruction or nerve conduction studies to assess possible cases of neuropathy.
All antiretroviral drugs are associated with different degrees of sexual dysfunction. The highest rates of dysfunction are associated with indinavir and the lowest with nevirapine .
If medication is the principal factor leading to sexual dysfunction, one can try another drug that has less influence on sexual response, such as nevirapine [2, 58] or atazanavir .
The use of PE-5 inhibitors is highly recommended in male sexual dysfunction , but one should be careful of drug interactions with antiretrovirals, particularly with protease inhibitors (especially ritonavir), the nonnucleoside reverse transcriptase inhibitor delavirdine, and ketoconazole. Because all of these drugs are metabolized by the cytochrome P-450 system, the dosages of PE-5 inhibitors should be reduced [47, 60]. In this situation, the recommended dosage of sildenafil is 25 mg every 48 hours (also reduced to 2.5 mg every 72 hours when also using ritonavir), of vardenafil is 2.5 mg every 24 hours, and of tadalafil is 10 mg every 72 hours [60–63].
Pharmacokinetic studies have demonstrated that sildenafil does not increase the blood levels of protease inhibitors, but indinavir, saquinavir, and ritonavir [60, 63] significantly increase sildenafil levels. There is, therefore, a risk of drug interaction between sildenafil and protease inhibitors, leading to hypotension and possible death in one case .
PE-5 inhibitors with longer half-lives may increase the risk of adverse effects for longer periods of time when combined with protease inhibitors. The use of sildenafil may be preferred because of its shorter half-life .
Poppers (amyl nitrate) are contraindicated by male users of PE-5 inhibitors because they lower blood pressure, especially in combination with PE-5 inhibitors .
If the patient meets the diagnostic criteria for hypogonadism, there are some options for testosterone replacement. Multiple formulations exist, ranging from intramuscular to transdermal and buccal administration. The latter avoids first-pass metabolism and results in more sustained serum testosterone concentrations .
Testosterone replacement is not prescribed for HIV patients without observed decreases in free testosterone blood levels because no improvements of sexual dysfunctions have been reported in this condition and the risks of treatment do not outweigh the benefits . Testosterone replacement therapy can sometimes be problematic even in hypogonadal males. One study reported three HIV-infected patients with ED who presented low testosterone and sex-hormone-binding globulin (SHBG) despite receiving long-term oxandrolone in addition to testosterone replacement therapy and HAART.
Discontinuation of oxandrolone led to the normalization or improvement of testosterone levels in all three patients, with symptomatic improvement in one patient. The authors hypothesized that the first-pass metabolism of orally administered oxandrolone may decrease the hepatic synthesis of SHBG, allowing exogenously supplied testosterone to be excreted .
In addition, testosterone replacement shows good results in improving the sexual dysfunction of most of hypogonadal HIV-infected individuals [44, 66–69]. The use of a topical testosterone gel  was shown to improve sexual function and also caused heightened erythropoiesis, weight gain, prevention of bone loss, increased energy, and improved mood .
Finally, some improvement in sexual desire has been reported in a few patients on HAART who were treated with letrozole, an aromatase inhibitor that inhibits the conversion of testosterone to estradiol. Thirteen men who have sex with men who were on HAART with LSD and also had raised estradiol levels were randomly selected to receive either parenteral testosterone or letrozole for six weeks. Standardized instruments demonstrated improvements in desire and the frequency of sexual acts in both treatment arms .
The psychotherapeutic approaches for the treatment of sexual dysfunction of HIV-infected people involve supportive and psychosexual therapy.
If the most relevant factor leading to sexual dysfunction is psychogenic, one can use supportive therapy in the period immediately after HIV diagnosis. Therapy should focus on demystifying the stigmas associated with HIV/AIDS as a lethal disease that is associated with non-conventional sexual behavior. The supportive approach would diminish fear and guilt and help individuals deal with discrimination .
Psychosexual therapy such as sensate focus or masturbatory training is indicated when the individual’s HIV seropositivity has already been accepted psychologically but sexual dysfunctions still remain. The approach is the same as that used for nonHIV-infected individuals with sexual dysfunctions.
3.3.4. Psychoeducational Approach to Safer Sex
A psychoeducational approach to safer sex is offered concomitant with the treatment of the sexual dysfunction. The approach always involves the patient and his or her partner. Safer sex counseling is fundamental for explaining the risks associated with contact with different strains of HIV, which favors the development of the resistance to antiretrovirals.
Finally, a psychoeducational approach should encourage lifestyle modifications including safer sex, exercise, modifications of cardiovascular risk factors, and education about the effects of recreational drug use .
An essential part of managing sexual dysfunction in HIV patients is counseling about maintaining safer sexual practices to minimize the risk of acquiring other sexually transmitted infections and transmitting HIV to others. It must be emphasized that having an undetectable plasma HIV viral load does not mean that an individual is no longer able to pass on the virus.
There is good evidence that the HIV viral load in seminal fluid is independent of plasma HIV-1 RNA levels . Even if intercourse occurs between HIV-positive concordant partners, the risks of sexual infections, transmission of drug-resistant HIV, and superinfection remain .
As Table 1 shows, most (12/15) of the clinical studies on HIV-positive male sexual dysfunctions took place from 1998 to 2007. The majority (11/15) addressed the role of HAART or hormonal changes in the sexual dysfunctions of HIV-positive men.
A possible role of antiretroviral drugs in the generation of sexual dysfunction is controversial. Whereas some studies have supported a role of antiretroviral therapy in sexual dysfunction [19, 23, 71], other studies have not found such an association [3, 18, 72]. In the HAART era, there are high rates of sexual dysfunction despite general health improvements.
Different methodological designs and the use or lack of standardized instruments are responsible for the controversial results regarding a possible association between sexual dysfunction and antiretrovirals. Just 4 of 15 studies (Table 1) used standardized measures in their evaluations of sexual dysfunctions. The different methodologies likely contribute to the varying results.
In contrast to depression, which was addressed by most of the studies, other psychogenic factors were not often investigated (Table 1).
In Table 2, we can see the scarcity of studies on the psychological interventions for sexual dysfunctions in HIV-positive individuals that aim to investigate the evidence for the clinical management of psychogenic sexual dysfunctions. Just one of the six studies addressed psychological treatment. Curiously, this study reported that the majority of the 34 HIV-positive homosexual men experienced an improvement of their sexual function. The problems were solved for 16 (76%) and improved for 3 (14%), whereas only 2 (10%) reported no change. However, the physical methods of treatment were more effective than psychological interventions  in this population.
Sexual functioning before HIV diagnosis, current physical and mental health, and psychosocial support are important factors for improving the sexual response. A medical team that is up to date on human sexuality is necessary for the diagnosis and treatment of sexual dysfunctions. When these conditions are preserved, the therapeutic results are good [41–43].
The problem is that it is often the case that sexual issues are not fully investigated by health professionals and few patients will talk about sexual problems spontaneously. As sexual dysfunctions are so prevalent in the general population and in people living with HIV, a lot of them, have not received medical care on their sexual difficulties.
Another important point in the successful diagnosis and treatment of sexual dysfunctions lies in the scarcity of health professionals with expertise in human sexuality. A private issue such as this one needs professionals with the ability to address these sensitive issues with their patients. Otherwise, patients are not likely to disclose their sexual problems to their doctors. When a patient receives medical care on them sexual difficulties, they feels valued and will be more open to engage in adherence to both medications and safer sex strategies.
Sexual dysfunctions of HIV-positive men are well documented. Several researchers have investigated factors associated with sexual dysfunction in this population. The association between sexual dysfunction and antiretrovirals, particularly protease inhibitors, has been reported in many studies. Some important findings have contributed to understanding the pathophysiological issues associated with sexual dysfunction, but it is still unclear how antiretrovirals cause sexual dysfunctions. The clinical trials show that testosterone replacement is beneficial in terms of sexual functioning. With regard to psychological interventions, there are not enough studies to provide any evidence of a therapeutic effect.
- A. Danoff, “Endocrinologic complications of HIV infection,” Medical Clinics of North America, vol. 80, no. 6, pp. 1453–1469, 1996.
- J. Collazos, “Sexual dysfunction in the highly active antiretroviral therapy era,” AIDS Reviews, vol. 9, no. 4, pp. 237–245, 2007.
- J. Cove and J. Petrak, “Factors associated with sexual problems in HIV-positive gay men,” International Journal of STD and AIDS, vol. 15, no. 11, pp. 732–736, 2004.
- M. T. Scanavino and C. H. Abdo, “Sexual dysfunctions among people living with aids in Brazil,” Clinics, vol. 65, no. 5, pp. 511–519, 2010.
- B. R. S. Rosser, J. M. Gobby, and W. P. Carr, “The unsafe sexual behavior of persons,” Journal of Sex Education and Therapy, vol. 24, no. 1-2, pp. 18–28, 1999.
- G. Newshan, B. Taylor, and R. Gold, “Sexual functioning in ambulatory men with HIV/AIDS,” International Journal of STD and AIDS, vol. 9, no. 11, pp. 672–676, 1998.
- M. Stein, D. S. Herman, E. Trisvan, P. Pirraglia, P. Engler, and B. J. Anderson, “Alcohol use and sexual risk behavior among human immunodeficiency virus-positive persons,” Alcoholism: Clinical and Experimental Research, vol. 29, no. 5, pp. 837–843, 2005.
- J. Bancroft, L. Carnes, and E. Janssen, “Unprotected anal intercourse in HIV-positive and HIV-negative gay men: the relevance of sexual arousability, mood, sensation seeking, and erectile problems,” Archives of Sexual Behavior, vol. 34, no. 3, pp. 299–305, 2005.
- L. Hijazi, R. Nandwani, and P. Kell, “Medical management of sexual difficulties in HIV-positive individuals,” International Journal of STD and AIDS, vol. 13, no. 9, pp. 587–592, 2002.
- R. Fitzpatrick, D. Frost, and G. Ikkos, “Survey of psychological disturbance in patients attending a sexually transmitted diseases clinic,” Genitourinary Medicine, vol. 62, no. 2, pp. 111–115, 1986.
- M. P. Trotta, A. Ammassari, R. Murri, A. D. Monforte, and A. Antinori, “Sexual dysfunction in HIV infection,” The Lancet, vol. 369, no. 9565, pp. 905–906, 2007.
- M. P. Trotta, A. Ammassari, R. Murri et al., “Self-reported sexual dysfunction is frequent among HIV-infected persons and is associated with suboptimal adherence to antiretrovirals,” AIDS Patient Care and STDs, vol. 22, no. 4, pp. 291–299, 2008.
- M. P. Trotta, A. Ammassari, A. Cozzi-Lepri et al., “Adherence to highly active antiretroviral therapy is better in patients receiving non-nucleoside reverse transcriptase inhibitor-containing regimens than in those receiving protease inhibitor-containing regimens,” AIDS, vol. 17, no. 7, pp. 1099–1102, 2003.
- P. F. Barroso, M. Schechter, P. Gupta, C. Bressan, A. Bomfim, and L. H. Harrison, “Adherence to antiretroviral therapy and persistence of HIV RNA in semen,” Journal of Acquired Immune Deficiency Syndromes, vol. 32, no. 4, pp. 435–440, 2003.
- M. J. Miguez-Burbano, L. Espinoza, and J. E. Lewis, “HIV treatment adherence and sexual functioning,” AIDS and Behavior, vol. 12, no. 1, pp. 78–85, 2008.
- L. Mao, C. E. Newman, M. R. Kidd, D. C. Saltman, G. D. Rogers, and S. C. Kippax, “Self-reported sexual difficulties and their association with depression and other factors among gay men attending high HIV-caseload general practices in Australia,” Journal of Sexual Medicine, vol. 6, no. 5, pp. 1378–1385, 2009.
- A. D. Bouhnik, M. Préau, M. A. Schiltz et al., “Sexual difficulties in people living with HIV in France—results from a large representative sample of outpatients attending French hospitals (ANRS-EN12-VESPA),” AIDS and Behavior, vol. 12, no. 4, pp. 670–676, 2008.
- N. F. Crum-Cianflone, M. Bavaro, B. Hale et al., “Erectile dysfunction and hypogonadism among men with HIV,” AIDS Patient Care and STDs, vol. 21, no. 1, pp. 9–19, 2007.
- D. Asboe, J. Catalan, S. Mandalia et al., “Sexual dysfunction in HIV-positive men is multi-factorial: a study of prevalence and associated factors,” AIDS Care, vol. 19, no. 8, pp. 955–965, 2007.
- G. Guaraldi, K. Luzi, R. Murri et al., “Sexual dysfunction in HIV-infected men: role of antiretroviral therapy, hypogonadism and lipodystrophy,” Antiviral Therapy, vol. 12, no. 7, pp. 1059–1065, 2007.
- D. Richardson, H. Lamba, D. Goldmeier, A. Nalabanda, and J. R. W. Harris, “Factors associated with sexual dysfunction in men with HIV infection,” International Journal of STD and AIDS, vol. 17, no. 11, pp. 764–767, 2006.
- H. Lamba, D. Goldmeier, N. E. Mackie, and G. Scullard, “Antiretroviral therapy is associated with sexual dysfunction and with increased serum oestradiol levels in men,” International Journal of STD and AIDS, vol. 15, no. 4, pp. 234–237, 2004.
- J. Collazos, E. Martínez, J. Mayo, and S. Ibarra, “Sexual dysfunction in HIV-infected patients treated with highly active antiretroviral therapy,” Journal of Acquired Immune Deficiency Syndromes, vol. 31, no. 3, pp. 322–326, 2002.
- J. Collazos, E. Martinez, J. Mayo, and S. Ibarra, “Sexual hormones in HIV-infected patients: the influence of antiretroviral therapy,” AIDS, vol. 16, no. 6, pp. 934–937, 2002.
- W. Schrooten, R. Colebunders, M. Youle et al., “Sexual dysfunction associated with protease inhibitor containing highly active antiretroviral treatment,” AIDS, vol. 15, no. 8, pp. 1019–1023, 2001.
- S. Sollima, M. Osio, F. Muscia et al., “Protease inhibitors and erectile dysfunction,” AIDS, vol. 15, no. 17, pp. 2331–2333, 2001.
- J. Catalan and J. Meadows, “Sexual dysfunction in gay and bisexual men with HIV infection: evaluation, treatment and implications,” AIDS Care, vol. 12, no. 3, pp. 279–286, 2000.
- J. A. Ciesla and J. E. Roberts, “Meta-analysis of the relationship between HIV infection and risk for depressive disorders,” American Journal of Psychiatry, vol. 158, no. 5, pp. 725–730, 2001.
- N. F. Crum, K. J. Furtek, P. E. Olson, C. L. Amling, and M. R. Wallace, “A review of hypogonadism and erectile dysfunction among HIV-infected men during the pre- and post-HAART eras: diagnosis, pathogenesis, and management,” AIDS Patient Care and STDs, vol. 19, no. 10, pp. 655–671, 2005.
- C. Bell, D. Richardson, M. Wall, and D. Goldmeier, “HIV-associated female sexual dysfunction—clinical experience and literature review,” International Journal of STD and AIDS, vol. 17, no. 10, pp. 706–709, 2006.
- D. Goldmeier, G. Scullard, M. Kapembwa, H. Lamba, and G. Frize, “Does increased aromatase activity in adipose fibroblasts cause low sexual desire in patients with HIV lipodystrophy?” Sexually Transmitted Infections, vol. 78, no. 1, pp. 64–66, 2002.
- H. W. Daniell, “Hypogonadism in men consuming sustained-action oral opioids,” Journal of Pain, vol. 3, no. 5, pp. 377–384, 2002.
- T. F. Lue, “Erectile dysfunction,” The New England Journal of Medicine, vol. 342, no. 24, pp. 1802–1813, 2000.
- E. Bruckert, P. Giral, H. M. Heshmati, and G. Turpin, “Men treated with hypolipidaemic drugs complain more frequently of erectile dysfunction,” Journal of Clinical Pharmacy and Therapeutics, vol. 21, no. 2, pp. 89–94, 1996.
- E. D. Moreira, C. H. N. Abdo, E. B. Torres, C. F. L. Lôbo, and J. A. S. Fittipaldi, “Prevalence and correlates of erectile dysfunction: results of the Brazilian study of sexual behavior,” Urology, vol. 58, no. 4, pp. 583–588, 2001.
- K. E. Rogstad, R. Shah, G. Tesfaladet, M. Abdullah, and I. Ahmed-Jushuf, “Cardiovascular autonomic neuropathy in HIV infected patients,” Sexually Transmitted Infections, vol. 75, no. 4, pp. 264–267, 1999.
- B. Srilatha and P. G. Adaikan, “Estrogen and phytoestrogen predispose to erectile dysfunction: do ER-α and ER-β in the cavernosum play a role?” Urology, vol. 63, no. 2, pp. 382–386, 2004.
- B. Srilatha, Y. S. Chong, and P. G. Adaikan, “Relevance of oestradiol-testosterone balance in erectile dysfunction patients' prognosis,” Singapore Medical Journal, vol. 48, no. 2, pp. 114–118, 2007.
- Y. Yang, T. Ikezoe, T. Takeuchi et al., “HIV-1 protease inhibitor induces growth arrest and apoptosis of human prostate cancer LNCaP cells in vitro and in vivo in conjunction with blockade of androgen receptor STAT3 and AKT signaling,” Cancer Science, vol. 96, no. 7, pp. 425–433, 2005.
- M. E. Baker, D. A. Vaughn, and D. D. Fanestil, “Inhibition by protease inhibitors of binding of adrenal and sex steroid hormones,” Journal of Supramolecular Structure, vol. 9, no. 3, pp. 421–426, 1978.
- M. D. Cheitlin, A. M. Hutter Jr., R. G. Brindis, et al., “ACC/AHA expert consensus document. Use of sildenafil (Viagra) in patients with cardiovascular disease. American College of Cardiology/American Heart Association,” Journal of the American College of Cardiology, vol. 33, no. 1, pp. 273–282, 1999.
- S. Schrader, A. Mills, M. Scheperle, and J. E. Block, “Improvement in sexual functioning and satisfaction in nonresponders to testosterone gel: clinical effectiveness in hypogonadal, HIV-positive males,” Clinical Cornerstone, vol. 7, supplement 4, pp. S26–S31, 2005.
- A. D. Seftel, R. J. Mack, A. R. Secrest, and T. M. Smith, “Restorative increases in serum testosterone levels are significantly correlated to improvements in sexual functioning,” Journal of Andrology, vol. 25, no. 6, pp. 963–972, 2004.
- J. G. Rabkin, G. J. Wagner, and R. Rabkin, “Testosterone therapy for human immunodeficiency virus-positive men with and without hypogonadism,” Journal of Clinical Psychopharmacology, vol. 19, no. 1, pp. 19–27, 1999.
- G. J. Wagner and J. G. Rabkin, “Testosterone therapy for clinical symptoms of hypogonadism in eugonadal men with AIDS,” International Journal of STD and AIDS, vol. 9, no. 1, pp. 41–44, 1998.
- A. Lawlor and A. Braunack-Mayer, “Doctors' views about the importance of shared values in HIV positive patient care: a qualitative study,” Journal of Medical Ethics, vol. 30, no. 6, pp. 539–543, 2004.
- R. C. Rosen, J. A. Catania, A. A. Ehrhardt et al., “The Bolger conference on PDE-5 inhibition and HIV risk: implications for health policy and prevention,” Journal of Sexual Medicine, vol. 3, no. 6, pp. 960–973, discussion 73–75, 2006.
- R. Basson, “Women's sexual function and dysfunction: current uncertainties, future directions,” International Journal of Impotence Research, vol. 20, no. 5, pp. 4664–4678, 2008.
- C. Gwandure, “Sexual assault in childhood: risk HIV and AIDS behaviours in adulthood,” AIDS Care, vol. 19, no. 10, pp. 1313–1315, 2007.
- J. B. Greenberg, “Childhood sexual abuse and sexually transmitted diseases in adults: a review of and implications for STD/HIV programmes,” International Journal of STD and AIDS, vol. 12, no. 12, pp. 777–783, 2001.
- K. Whetten, J. Leserman, K. Lowe et al., “Prevalence of childhood sexual abuse and physical trauma in an HIV-positive sample from the deep south,” The American Journal of Public Health, vol. 96, no. 6, pp. 1028–1030, 2006.
- R. W. Lewis, K. S. Fugl-Meyer, R. Bosch et al., “Epidemiology/risk factors of sexual dysfunction,” Journal of Sexual Medicine, vol. 1, no. 1, pp. 35–39, 2004.
- E. Coleman, B. R. Rosser, and N. Strapko, “Sexual and intimacy dysfunction among homosexual men and women,” Psychiatric Medicine, vol. 10, no. 2, pp. 257–271, 1992.
- A. E. M. Speckens, M. W. Hengeveld, A. G. A. B. Lycklama Nijeholt, A. M. Van Hemert, and K. E. Hawton, “Discrimination between psychogenic and organic erectile dysfunction,” Journal of Psychosomatic Research, vol. 37, no. 2, pp. 135–145, 1993.
- J. P. Hatch, A. M. de la Peña, and J. G. Fisher, “Psychometric differentiation of psychogenic and organic erectile disorders,” Journal of Urology, vol. 138, no. 4, pp. 781–783, 1987.
- K. J. Somers and K. L. Philbrick, “Sexual dysfunction in the medically ill,” Current Psychiatry Reports, vol. 9, no. 3, pp. 247–254, 2007.
- R. C. Rosen, A. Riley, G. Wagner, I. H. Osterloh, J. Kirkpatrick, and A. Mishra, “The international index of erectile function (IIEF): a multidimensional scale for assessment of erectile dysfunction,” Urology, vol. 49, no. 6, pp. 822–830, 1997.
- L. C. Hofbauer and A. E. Heufelder, “Endocrine implications of human immunodeficiency virus infection,” Medicine, vol. 75, no. 5, pp. 262–278, 1996.
- J. Collazos, J. Mayo, E. Martínez, and S. Ibarra, “Association between sexual disturbances and sexual hormones with specific antiretroviral drugs,” AIDS, vol. 16, no. 9, pp. 1294–1295, 2002.
- E. Bernal, M. Masiá, S. Padilla, and F. Gutiérrez, “Unexpected improvement of sexual dysfunction during atazanavir therapy,” AIDS, vol. 19, no. 13, pp. 1440–1441, 2005.
- C. Merry, M. G. Barry, M. Ryan et al., “Interaction of sildenafil and indinavir when co-administered to HIV-positive patients,” AIDS, vol. 13, no. 15, pp. F101–F107, 1999.
- H. A. Fink, R. M. Donald, I. R. Rutks, D. B. Nelson, and T. J. Wilt, “Sildenafil for male erectile dysfunction: a systematic review and meta-analysis,” Archives of Internal Medicine, vol. 162, no. 12, pp. 1349–1360, 2002.
- T. Klotz, “Vardenafil increases penile rigidity and tumescence in erectile dysfunction patients: a RigiScan and pharmacokinetic study,” World Journal of Urology, vol. 19, no. 1, pp. 32–39, 2001.
- G. J. Muirhead, M. B. Wulff, A. Fielding, D. Kleinermans, and N. Buss, “Pharmacokinetic interactions between sildenafil and saquinavir/ritonavir,” The British Journal of Clinical Pharmacology, vol. 50, no. 2, pp. 99–107, 2000.
- M. C. S. Hall and S. Ahmad, “Interaction between sildenafil and HIV-1 combination therapy,” The Lancet, vol. 353, no. 9169, pp. 2071–2072, 1999.
- P. Wasserman, S. Segal-maurer, and D. Rubin, “Low sex hormone-binding globulin and testosterone levels in association with erectile dysfunction among human immunodeficiency virus-infected men receiving testosterone and oxandrolone,” Journal of Sexual Medicine, vol. 5, no. 1, pp. 241–247, 2008.
- J. Cofrancesco, J. J. Whalen, and A. S. Dobs, “Testosterone replacement treatment options for HIV-infected men,” Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology, vol. 16, no. 4, pp. 254–265, 1997.
- J. G. Rabkin, R. Rabkin, and G. J. Wagner, “Testosterone treatment of clinical hypogonadism in patients with HIV/AIDS,” International Journal of STD and AIDS, vol. 8, no. 9, pp. 537–545, 1997.
- J. G. Rabkin, G. J. Wagner, and R. Rabkin, “A double-blind, placebo-controlled trial of testosterone therapy for HIV-positive men with hypogonadal symptoms,” Archives of General Psychiatry, vol. 57, no. 2, pp. 141–147, discussion 55-56, 2000.
- D. Richardson, D. Goldmeier, G. Frize et al., “Letrozole versus testosterone. a single-center pilot study of HIV-infected men who have sex with men on highly active anti-retroviral therapy (HAART) with hypoactive sexual desire disorder and raised estradiol levels,” Journal of Sexual Medicine, vol. 4, no. 2, pp. 502–508, 2007.
- H. Zhang, G. Dornadula, M. Beumont et al., “Human immunodeficiency virus type 1 in the semen of men receiving highly active antiretroviral therapy,” The New England Journal of Medicine, vol. 339, no. 25, pp. 1803–1809, 1998.
- A. R. Ende, V. Lo Re, M. J. DiNubile, and K. Mounzer, “Erectile dysfunction in an urban HIV-positive population,” AIDS Patient Care and STDs, vol. 20, no. 2, pp. 75–78, 2006.